Spruce Biosciences, Inc. (NASDAQ: SPRB)

Spruce Biosciences, Inc., a prominent player in the biotechnology industry, is dedicated to the development and commercialization of innovative therapies for rare endocrine disorders that have substantial unmet medical needs. The company's primary product candidate, tildacerfont, is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) receptor, which has the potential to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Spruce Biosciences is headquartered in the United States and operates in the highly competitive and rapidly evolving biotechnology industry. The company's main business activities involve the discovery, development, and commercialization of novel therapies for rare endocrine disorders. Spruce Biosciences' competitive advantages include its focus on developing novel therapies for rare endocrine disorders, its experienced management team, and its strong intellectual property portfolio.

The company generates revenue through the development and commercialization of its product candidate, tildacerfont. The primary products and services offered by Spruce Biosciences include tildacerfont, a novel therapy for classic CAH, and other potential products in development for rare endocrine disorders.

Spruce Biosciences' customers are primarily specialty endocrinology clinics and hospitals that treat patients with rare endocrine disorders. The company plans to build a highly specialized commercial organization to support the commercialization of tildacerfont, if approved, in the United States.

The clinical development of tildacerfont is focused on the treatment of adults and children with classic CAH, as well as for the treatment of polycystic ovary syndrome (PCOS). The company is currently conducting a placebo-controlled, double-blind Phase 2b clinical trial in 96 adult patients with classic CAH and a Phase 2 open-label clinical trial in children two to 17 years of age with classic CAH. Additionally, Spruce Biosciences has initiated a Phase 2 proof-of-concept clinical trial to evaluate the safety and efficacy of tildacerfont in females with PCOS and elevated adrenal androgens.

Spruce Biosciences' competitive position is strengthened through its strategic partnerships. The company has partnered with Kaken Pharmaceutical Co. Ltd. to develop and commercialize tildacerfont for the treatment of CAH in Japan. Under the terms of the agreement, the company will receive an upfront payment of $15.0 million from Kaken and will be eligible to receive additional payments upon the achievement of future development and commercial milestones, as well as tiered double-digit royalties on net sales in Japan.

Furthermore, Spruce Biosciences has licensed its intellectual property to Eli Lilly and Company (Lilly) and Kaken Pharmaceutical Co. Ltd. Under the Lilly License Agreement, Lilly granted Spruce Biosciences an exclusive, worldwide, royalty-bearing, sublicensable license to research, develop, commercialize, make, have made, use, sell, offer to sell, and import Lilly's CRF1 receptor antagonist compounds, including tildacerfont.